Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VANIQA

« Back to Dashboard
Vaniqa is a drug marketed by Skinmedica and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug.

This drug has twenty-four patent family members in eighteen countries.

The generic ingredient in VANIQA is eflornithine hydrochloride. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the eflornithine hydrochloride profile page.

Summary for Tradename: VANIQA

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2

Pharmacology for Tradename: VANIQA

Clinical Trials for: VANIQA

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Status: Recruiting Condition: Familial Adenomatous Polyposis

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Status: Withdrawn Condition: Familial Adenomatous Polyposis

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Status: Recruiting Condition: Adenomatous Polyp

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Status: Completed Condition: Cervical Cancer; Precancerous Condition

S0820, Adenoma and Second Primary Prevention Trial
Status: Recruiting Condition: Colorectal Neoplasms

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Status: Completed Condition: Precancerous Condition

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Status: Terminated Condition: Colorectal Cancer; Familial Adenomatous Polyposis

Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Status: Completed Condition: Non-melanomatous Skin Cancer

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
Status: Completed Condition: Prostate Cancer

Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Status: Withdrawn Condition: Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skinmedica
VANIQA
eflornithine hydrochloride
CREAM;TOPICAL021145-001Jul 27, 2000RXYes5,648,394<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VANIQA

Country Document Number Publication Date
JapanH08507785Aug 20, 1996
Canada2158041Apr 03, 2001
Poland174475Aug 31, 1998
World Intellectual Property Organization (WIPO)9421217Sep 29, 1994
Romania117413Mar 29, 2002
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc